Sana Biotechnology Reports 14-Month Follow-Up Results for UP421 Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy SANA?
Sana Biotechnology announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune platform, HIP, technology, into a patient with type 1 diabetes without any immunosuppression. The study is being conducted in partnership with Uppsala University Hospital. Results from more than 1 year after cell transplantation demonstrate sustained survival and function of pancreatic beta cells, as measured by the presence of circulating C-peptide, a biomarker of endogenous insulin production by the transplanted beta cells. C-peptide levels also increase in response to a mixed meal tolerance test, consistent with insulin secretion in response to a meal. Fasting and MMTT-stimulated C-peptide levels at month 14 are comparable to those observed in the first six months of the study and exceed levels measured at months 9 and 12. Between months 12 and 14, the patient achieved tighter glycemic control, and the improved insulin secretion at month 14 underscores the importance of glucose control in optimizing pancreatic beta cell function. No safety issues were identified in the study.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SANA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SANA
Wall Street analysts forecast SANA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.880
Low
7.00
Averages
8.00
High
9.00
Current: 2.880
Low
7.00
Averages
8.00
High
9.00
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SANA BIOTECHNOLOGY INC - HIP-MODIFIED ISLETS DEMONSTRATE SAFETY, IMMUNE EVASION, AND INSULIN PRODUCTION AFTER 14 MONTHS
Safety of In-Chip Modified Islets: Recent studies indicate that in-chip modified islets demonstrate safety for use in medical applications.
Immune Evasion: The modified islets show promising results in evading immune responses, which is crucial for their effectiveness in transplantation.
Insulin Production: These islets are capable of producing insulin, which is essential for managing blood sugar levels in diabetic patients.
14-Month Evaluation: The findings are based on evaluations conducted over a 14-month period, highlighting the long-term viability of the modified islets.
See More
Sana Biotechnology Reports Q4 Results with Expanded Losses
- Financial Overview: Sana Biotechnology reported an adjusted net loss of $44.74 million for Q4, or $0.16 per share, a decrease from $54.79 million and $0.23 per share last year, indicating efforts in cost management; however, the overall net loss expanded to $58.83 million, reflecting ongoing financial challenges.
- R&D Progress and Milestones: The company aims to generate human proof-of-concept data for SC451 and SG293 within the next 12-18 months, with SC451 targeting type 1 diabetes and SG293 focusing on blood cancers, suggesting that advancements in these critical therapeutic areas could position Sana competitively in the market.
- Cash Flow and Financing Status: As of Q4 2025, Sana reported a cash position of $138.4 million, with an expected runway into late 2026, ensuring funding for R&D and operations, which enhances investor confidence in its long-term growth prospects.
- Clinical Trials and Regulatory Interactions: Multiple interactions with regulators have bolstered confidence in Sana's manufacturing processes and clinical trial plans, with an IND application for SC451 anticipated as early as 2026, followed by Phase 1 trials, demonstrating the company's proactive approach to advancing its product pipeline.
See More
Sana Biotechnology Reports Q4 Earnings Miss
- Earnings Report Disappointment: Sana Biotechnology's Q4 GAAP EPS of -$0.21 missed expectations by $0.07, indicating ongoing challenges in achieving profitability and raising concerns among investors.
- Deteriorating Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $138.4 million, down from $152.5 million in 2024, primarily due to operational cash outflows of $143.8 million, highlighting financial strain.
- Impact of Financing Activities: Despite high operational costs, Sana secured net proceeds of $126.4 million from equity financings and $2.7 million from stock option exercises and employee stock purchase plans, partially alleviating cash flow pressures and demonstrating some financial resilience.
- Cautious Market Reaction: Given the disappointing financial performance and tight cash flow, the market remains cautious about Sana Biotechnology's outlook, which may affect its stock price performance, prompting investors to monitor future financial improvement efforts.
See More
Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.
See More
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.
See More
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's fusogen technology has achieved effective gene editing of hematopoietic stem cells in murine models, demonstrating potent cell specificity and stability, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Clinical Application Potential: This technology can overcome limitations of traditional bone marrow transplants and current ex vivo gene editing methods, such as the need for high doses of conditioning chemotherapy, thereby reducing risks of infections and secondary cancers, enhancing patient treatment experiences.
- Product Development Plans: Sana aims to file an IND for SG293 by 2027, which utilizes fusogen technology to generate CD19-targeted CAR T cells in vivo, targeting B-cell cancers and autoimmune diseases, indicating strong market potential.
- Scientific Validation: Recent research published shows that optimized virus-like particles (VLPs) can achieve effective gene editing in long-term human hematopoietic stem cells, further validating the fusogen technology's application potential across multiple cell types.
See More
SANA BIOTECHNOLOGY INC - HIP-MODIFIED ISLETS DEMONSTRATE SAFETY, IMMUNE EVASION, AND INSULIN PRODUCTION AFTER 14 MONTHS
Safety of In-Chip Modified Islets: Recent studies indicate that in-chip modified islets demonstrate safety for use in medical applications.
Immune Evasion: The modified islets show promising results in evading immune responses, which is crucial for their effectiveness in transplantation.
Insulin Production: These islets are capable of producing insulin, which is essential for managing blood sugar levels in diabetic patients.
14-Month Evaluation: The findings are based on evaluations conducted over a 14-month period, highlighting the long-term viability of the modified islets.
See More
Sana Biotechnology Reports Q4 Results with Expanded Losses
- Financial Overview: Sana Biotechnology reported an adjusted net loss of $44.74 million for Q4, or $0.16 per share, a decrease from $54.79 million and $0.23 per share last year, indicating efforts in cost management; however, the overall net loss expanded to $58.83 million, reflecting ongoing financial challenges.
- R&D Progress and Milestones: The company aims to generate human proof-of-concept data for SC451 and SG293 within the next 12-18 months, with SC451 targeting type 1 diabetes and SG293 focusing on blood cancers, suggesting that advancements in these critical therapeutic areas could position Sana competitively in the market.
- Cash Flow and Financing Status: As of Q4 2025, Sana reported a cash position of $138.4 million, with an expected runway into late 2026, ensuring funding for R&D and operations, which enhances investor confidence in its long-term growth prospects.
- Clinical Trials and Regulatory Interactions: Multiple interactions with regulators have bolstered confidence in Sana's manufacturing processes and clinical trial plans, with an IND application for SC451 anticipated as early as 2026, followed by Phase 1 trials, demonstrating the company's proactive approach to advancing its product pipeline.
See More
Sana Biotechnology Reports Q4 Earnings Miss
- Earnings Report Disappointment: Sana Biotechnology's Q4 GAAP EPS of -$0.21 missed expectations by $0.07, indicating ongoing challenges in achieving profitability and raising concerns among investors.
- Deteriorating Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $138.4 million, down from $152.5 million in 2024, primarily due to operational cash outflows of $143.8 million, highlighting financial strain.
- Impact of Financing Activities: Despite high operational costs, Sana secured net proceeds of $126.4 million from equity financings and $2.7 million from stock option exercises and employee stock purchase plans, partially alleviating cash flow pressures and demonstrating some financial resilience.
- Cautious Market Reaction: Given the disappointing financial performance and tight cash flow, the market remains cautious about Sana Biotechnology's outlook, which may affect its stock price performance, prompting investors to monitor future financial improvement efforts.
See More
Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.
See More
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.
See More
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's fusogen technology has achieved effective gene editing of hematopoietic stem cells in murine models, demonstrating potent cell specificity and stability, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Clinical Application Potential: This technology can overcome limitations of traditional bone marrow transplants and current ex vivo gene editing methods, such as the need for high doses of conditioning chemotherapy, thereby reducing risks of infections and secondary cancers, enhancing patient treatment experiences.
- Product Development Plans: Sana aims to file an IND for SG293 by 2027, which utilizes fusogen technology to generate CD19-targeted CAR T cells in vivo, targeting B-cell cancers and autoimmune diseases, indicating strong market potential.
- Scientific Validation: Recent research published shows that optimized virus-like particles (VLPs) can achieve effective gene editing in long-term human hematopoietic stem cells, further validating the fusogen technology's application potential across multiple cell types.
See More
